SMO is altered in 7.69% of medulloblastoma patients [3].

SMO is an inclusion criterion in 9 clinical trials for medulloblastoma, of which 8 are open and 1 is closed. Of the trials that contain SMO status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [4].

SMO is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain SMO status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].

SMO is altered in 1.75% of malignant solid tumor patients [3].

SMO is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain SMO status and malignant solid tumor as inclusion criteria, 3 are phase 2 (3 open) [4].

SMO is altered in 10.53% of desmoplastic/nodular medulloblastoma patients [3].

SMO is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain SMO status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

SMO is altered in 5.93% of central nervous system embryonal neoplasm patients [3].

SMO is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain SMO status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

SMO is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain SMO status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

SMO is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain SMO status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

SMO is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain SMO status and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

SMO is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain SMO status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

SMO is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain SMO status and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [4].

SMO is an inclusion criterion in 2 clinical trials for medulloblastoma, WNT-activated, of which 2 are open and 0 are closed. Of the trials that contain SMO status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

SMO is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain SMO status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

SMO is altered in 4.87% of meningioma patients [3].

SMO is an inclusion criterion in 1 clinical trial for meningioma, of which 0 are open and 1 is closed. Of the trial that contains SMO status and meningioma as inclusion criteria, 1 is phase 2 (0 open) [4].

SMO is altered in 2.78% of anaplastic oligodendroglioma patients [3].

SMO is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is altered in 3.0% of melanoma patients [3].

SMO is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SMO is altered in 1.97% of adenocarcinoma of the gastroesophageal junction patients [3].

SMO is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 1 is closed. Of the trial that contains SMO status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (0 open) [4].

SMO is altered in 2.2% of glioblastoma patients [3].

SMO is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is altered in 1.98% of non-small cell lung carcinoma patients [3].

SMO is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SMO is altered in 2.03% of malignant glioma patients [3].

SMO is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is altered in 1.96% of diffuse glioma patients [3].

SMO is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is altered in 1.59% of anaplastic ependymoma patients [3].

SMO is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is altered in 1.63% of bladder carcinoma patients [3].

SMO is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SMO is altered in 1.49% of high-grade glioma, NOS patients [3].

SMO is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains SMO status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is altered in 1.44% of gastric adenocarcinoma patients [3].

SMO is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMO status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

SMO is altered in 1.29% of anaplastic astrocytoma patients [3].

SMO is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is altered in 0.91% of pancreatic carcinoma patients [3].

SMO is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SMO is altered in 0.83% of biliary tract carcinoma patients [3].

SMO is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SMO is altered in 0.83% of multiple myeloma patients [3].

SMO is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

SMO is altered in 0.73% of malignant salivary gland neoplasm patients [3].

SMO is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMO status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

SMO is altered in 0.6% of B-cell non-hodgkin lymphoma patients [3].

SMO is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SMO is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains SMO status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains SMO status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains SMO status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains SMO status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains SMO status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains SMO status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains SMO status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

SMO is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMO status and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

SMO is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].